Developmental toxicology-new directions workshop: Refining testing strategies and study designs

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 92, Issue 5, 2011, Pages 404-412

  Brannen, Kimberly C ^a   Fenton, Suzanne E ^b   Hansen, Deborah K ^c   Harrouk, Wafa ^d   Kim, James H ^e   Shuey, Dana ^f  

^a CHARLES RIVER LABORATORIES   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^f ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Developmental toxicology; Refined study designs; Safety assessment; Testing strategies

Indexed keywords

ANIMAL TESTING REFINEMENT; CONTINUING EDUCATION; DEVELOPMENTAL TOXICOLOGY; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; TOXICOKINETICS; TOXICOLOGY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; FETAL DEVELOPMENT; HUMANS; MODELS, ANIMAL; MUTAGENICITY TESTS; RESEARCH DESIGN; RISK; RISK ASSESSMENT; SAFETY; TOXICITY TESTS; TOXICOLOGY;

ANIMALIA;

EID: 80054680893     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20326     Document Type: Review

References (13)

1. Abbott BD, Wolf CJ, Das KP, et al. 2009. Developmental toxicity of perfluorooctane sulfonate (PFOS) is not dependent on expression of peroxisome proliferator activated receptor-alpha (PPAR alpha) in the mouse. Reprod Toxicol 27:258-265.
2. Beyer BK, Chernoff N, Danielsson BR, et al. 2011. ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. Birth Def Res B 92:36-51.
3. Committee on Developmental Toxicology, Board on Environmental Studies and Toxicology, National Research Council. 2000. Scientific frontiers in developmental toxicology and risk assessment. Washington, DC: National Academy Press.
4. Cooper RL, Lamb JC, Barlow SM, et al. 2006. A tiered approach to life stages testing for agricultural chemical safety assessment. Crit Rev Toxicol 36:69-98.
5. Crofts F, Pino M, DeLise B, et al. 2004. Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Def Res 71:55-68.
6. Dix DJ, Houck KA, Martin M, et al. 2007. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 95:5-12.
7. ICH Harmonized Tripartite Guideline. 1997. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6. Available at:.
8. ICH Harmonized Tripartite Guideline. 2005. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. S5(R2). Available at:.
9. ICH Harmonized Tripartite Guideline. 2008. Dose selection for carcinogenicity studies of pharmaceuticals S1C(R2). Available at:.
10. ICH Harmonized Tripartite Guideline. 2009. Addendum to ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). Available at:.
11. Lou I, Wambaugh JF, Lau C, et al. 2009. Modeling single and repeated dose pharmacokinetics of PFOA in mice. Toxicol Sci 107:331-341.
12. Takacs ML, Abbott BD. 2007. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 95:108-117.
13. Yang JT, Rayburn H, Hynes RO. 1995. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 121:549-560.